(相关资料图)
恒瑞医药(600276)(600276.SH)公告,近日,公司子公司瑞石生物医药有限公司产品Edralbrutinib片用于治疗视神经脊髓炎谱系疾病(NMOSD)适应症获得美国食品药品监督管理局(“美国FDA”)授予的孤儿药资格认定。孤儿药又称罕见病药,是指用于预防、治疗、诊断罕见病的药品。本次获得美国FDA孤儿药资格认定,将有机会在产品研发、注册及商业化等方面享受美国的政策支持。
(相关资料图)
恒瑞医药(600276)(600276.SH)公告,近日,公司子公司瑞石生物医药有限公司产品Edralbrutinib片用于治疗视神经脊髓炎谱系疾病(NMOSD)适应症获得美国食品药品监督管理局(“美国FDA”)授予的孤儿药资格认定。孤儿药又称罕见病药,是指用于预防、治疗、诊断罕见病的药品。本次获得美国FDA孤儿药资格认定,将有机会在产品研发、注册及商业化等方面享受美国的政策支持。
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-07
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-06
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-05
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04
2023-05-04